# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-26T21:36:03.758364

---

**Idea Fidelity**

The paper follows the original idea closely. It exploits the staggered transposition of Directive 2016/2370 across 25 EU member states, uses Eurostat HICP transport price indices (with road and air as placebos), and implements a Callaway–Sant’Anna staggered DiD with triple-difference robustness checks. The empirical strategy focuses on whether de jure liberalization reduced national-average rail fares, mirroring the manifest’s research question. The only notable element from the manifest that the paper could emphasize further is the treatment intensity variation from incumbent market shares (RMMS data), which is mentioned in the idea statement but not operationalized in the paper.

**Summary**

The paper provides the first attempt to causally estimate the national welfare effects of the EU’s Fourth Railway Package using harmonized monthly rail fare indices. Exploiting staggered transposition across two cohorts, it finds no evidence that the legal opening of domestic passenger markets reduced rail fares at the national level; placebos (road/air fares) and triple-difference specifications corroborate the null. The paper interprets the null as evidence of a de jure–de facto gap in competition, with liberalization confined to a few routes and thus too localized to move aggregate price indices.

**Essential Points**

1. **Parallel Trends / Pre-Trends Evidence**: The credibility of the staggered DiD hinges on the parallel trends assumption between early and late transposers. The paper does not present formal evidence (event-study graphs or pre-trend tests) to support this. Given that regulatory transposition could correlate with institutional capacity, political cycles, or pre-existing fare dynamics, graphical or regression-based checks are essential. Please include event-study plots of rail fares (and ideally the placebo sectors) relative to transposition and report statistical tests for differential pre-trends. Without this, it is difficult to trust the ATT estimate, especially since the point estimates for early and late cohorts differ in sign.

2. **COVID-19 Confounding & Control Group Validity**: The bulk of the late-cohort post-treatment period coincides with the 2020 pandemic, which had heterogeneous effects across countries and transport modes. Although triple-difference specifications attempt to absorb common shocks, COVID shocks likely affected rail, road, and air differently (lockdowns hit air travel harder, PSO services less so). The paper’s strategy of comparing treated units to “not-yet-treated” late adopters may fail if the pandemic shock timing aligns with treatment timing, violating the parallel-trends assumption. You should demonstrate that the estimated ATT is not driven by COVID-related demand shocks—e.g., by (a) using a control group of late adopters whose treatment date was delayed beyond the pandemic peak, (b) interacting pandemic indicators with time fixed effects to soak up differential trends, or (c) truncating the sample before the pandemic for all cohorts and showing consistent results in a placebo “fake” treatment setting.

3. **Treatment Intensity / Mechanism**: The paper treats transposition as a sharp binary treatment, yet the manifest highlighted pre-existing incumbent market share variation and route-level entry (Sweden/Czechia/Italy). The aggregate HICP index may mask heterogeneity in treatment intensity, and countries differed widely in the extent actual competition materialized. Without accounting for this, the null could stem from low take-up rather than policy ineffectiveness. Consider leveraging available data on incumbent market shares or the presence of actual open-access operators (e.g., number of new entrants, high-speed route competition) to create an interaction or heterogeneity analysis. Alternatively, use treatment intensity (e.g., share of passenger-kilometers exposed to competition) to show whether areas with stronger actual entry show any fare impact. This will help disentangle a “liberalization illusion” from an “implementation gap” and strengthen the policy conclusion.

If these points cannot be addressed, the paper should be reconsidered for rejection because the core identification relies on assumptions that are currently unsupported.

**Suggestions**

1. **Pre-trend Visuals/Tests**: Include an event-study figure showing dynamic ATT estimates (e.g., 12 months before to 24 months after transposition) for rail fares and, if possible, for placebo sectors. Overlaying the dynamic estimates of early and late cohorts would explicitly test the parallel-trends assumption and help readers assess whether the pre-treatment slopes are indeed parallel. In addition, report a regression-based pre-trend test (e.g., interact the time dummies with a treatment indicator for periods before transposition or conduct a joint F-test on the pre-period coefficients).

2. **Alternative Control Groups**: Because COVID overlaps with the late treatment group, consider constructing an alternative control group consisting of countries whose treatment took effect after December 2020 (if available) or non-EU EU neighbors with similar fare trajectories but no transposition. If such data are unavailable, you might use synthetic control methods or augment the DiD with country-specific time trends to capture diverging pandemic responses.

3. **Incorporate Market Structure Data**: Utilize available RMMS data on incumbent market share or new entrant presence to refine your treatment definition. For example, interact the treatment indicator with a measure of incumbent market share or with an indicator for actual entry (e.g., presence of competing services), and estimate whether more competitive markets exhibited fare declines. This would also allow you to speak directly to the de jure/de facto narrative: if countries with actual open-access entry still show null effects, the explanation must lie elsewhere (e.g., weak pass-through). Conversely, if these countries do show declines, then the aggregate null reflects limited take-up.

4. **Quantities and Demand-side Checks**: While the paper focuses on prices, the liberalization might also show up in quantities (passenger-km) or modal share shifts. Augment the analysis with the quarterly rail passenger-km data and modal split (annual) as secondary outcomes. If competitive entry increased ridership even without price effects, that is a different policy story. Conversely, if both fares and quantities are flat, the case for the liberalization illusion strengthens.

5. **Placebo Tests Beyond Road/Air**: Expand placebo and falsification exercises. For example, test whether the treatment affects unrelated consumer goods or services (e.g., electricity or postal services) to ensure there are no spurious policy anticipation effects or common shocks misattributed to transposition timing. You could also conduct “fake treatment” tests where you assign transposition dates to untreated countries and re-estimate the ATT.

6. **Mechanism Discussion / PSO Transition**: The discussion currently emphasizes barriers like PSO contracts and incumbency. Strengthen this by describing the timeline of Regulation 2016/2338 (competitive PSO tendering) and whether any countries had already started competitive procurement before 2023. Clarify whether the data window (ending 2025) captures any of these procurement effects, which would change the interpretation of “lack of impact.” You might also link the null result to specific institutional frictions (e.g., infrastructure access charges, network regulation) with citations to case studies.

7. **Inference and Standard Errors**: With 25 clusters, results may be sensitive to the choice of inference method. While you mention using wild cluster bootstrap, the tables report conventional clustered SEs. Either (a) implement and report wild cluster bootstrap $p$-values for the main ATT estimates, or (b) show that the bootstrap results produce qualitatively identical conclusions. This is especially important for interpreting the early cohort estimate (–7%), which is statistically insignificant but economically large.

8. **Clarify Sample and Outcome Definitions**: There is a minor inconsistency: Table 1 reports 27 countries, but the text mentions the 25 rail-operating EU members. Specify whether the EU27 count includes non-rail countries (e.g., Cyprus, Malta) and how missing data are handled. Similarly, clarify whether the HICP indices reflect a pure rail price index or whether they include services like intercity vs. commuter fares. This transparency aids replication and contextualization.

9. **Supplemental Material or Code**: Provide the estimation code and data processing scripts (especially for the Callaway–Sant’Anna estimator) in the appendix or online repository. This will help validate the approach and allow other researchers to build on the exercise.

Overall, the paper is well-focused and addresses an important policy question, but the empirical credibility would be greatly enhanced by bolstering the identification argument and exploring heterogeneity by actual implementation.
